The effects of brand-generic substitution in antiepileptic treatment
cytuj
pobierz pliki
RIS BIB ENDNOTEChoose format
RIS BIB ENDNOTEThe effects of brand-generic substitution in antiepileptic treatment
Publication date: 02.12.2016
Public Health and Governance, 2016, Volume 14, Issue 4, pp. 254 - 258
https://doi.org/10.4467/20842627OZ.16.026.5895Authors
The effects of brand-generic substitution in antiepileptic treatment
The chronic character of the disease has a significant impact on expenses borne by individual patients and by the health care system. Patients diagnosed with epilepsy need a long-term treatment, which is often expensive. In order to minimize the costs, doctors are increasingly turning to prescribing cheaper generic drugs. On the one hand, from an economic perspective, such a solution is cost-effective; on the other hand, the choice of an inadequate treatment may have serious consequences for the patient’s health. Patients using drugs with a narrow therapeutic index should be careful because of differences in bioequivalence of medicinal products. An inadequate alteration of the treatment for epilepsy, either by replacing the original drug with a generic one or by replacing one generic drug with another, may adversely affect the patient’s condition. It is important, then, that therapeutic decisions should not be guided chiefly by considerations of cost reduction for the patient, but first of all by possible future health effects.
Skrzypczak Z., Haczyński J., Światowy rynek farmaceutyczny w dobie kryzysu gospodarczego, “Problemy Zarządzania” 2012; 11, 1 (41); 2: 128–145.
Skrzypczak Z., Haczyński J., Struktura rynku farmaceutycznego wg rodzaju sprzedawanych leków, “Problemy Zarządzania” 2012; 11, 1 (41); 2: 138 – 145.
Gidal B., Tobjorn T., Substitution of generic drugs in epilepsy: Is there cause for concern?, “Epilepsia” 2008; 49 (Suppl. 9): 56–62.
Rascati K., Richards K., Johnsrud M., Effects of Antiepileptic Drug Substitutions on Epileptic Events Requiring Acute Care, “Pharmacotherapy” 2009; 29 (7): 769–774.
Lewek P., Kardas P., Generic drugs: The benefits and risks of making the switch, “The Journal of Family Practice” 2010; 59 (11): 634–640.
Staniszewska A., Co warto wiedzieć o lekach generycznych, “Medycyna i Pasje” 2010; 4 (9): 14–19.
Grochowska M., Przebieg badań klinicznych leków, “Biomedical” 2011, http://www.biomedical.pl/zdrowie/przebieg-badan-klinicznych-lekow-1778.html; accessed: 19.12.2015.
Żukowski P., Badania biorównoważności i ich monitorowanie, in: Walter M. (ed), Badania kliniczne – organizacja, nadzór, monitorowanie, Onipharma, Warszawa 2004: 291–294.
Stańczak A., Leki oryginalne, czy leki generyczne, “Aptekarz Polski” 2011; 63 (41), http://www.aptekarzpolski.pl/index.php?option=com_content&task=view&id=1068&Itemid=108; accessed: 19.12.2015.
Kaczmarek Ł., Innowacyjne generyki przyszłością gospodarki, “Laboratorium” 2012; 5–6: 6–9.
Wkład innowacyjnego przemysłu farmaceutycznego w rozwój polskiej gospodarki, Raport PwC, 2011, http://www.infarma.pl/uploads/media/PwC_Raport.pdf; accessed: 23.12.2015.
Evans J., Generic and Brand-Name AEDs Bioequivalent, “Internal Medicine News” 2010; June: 18.
Information: Public Health and Governance, 2016, Volume 14, Issue 4, pp. 254 - 258
Article type: Original article
Titles:
The effects of brand-generic substitution in antiepileptic treatment
The effects of brand-generic substitution in antiepileptic treatment
Faculty of Health Sciences, Medical University of Warsaw
Department of Experimental and Clinical Pharmacology, Medical University of Warsaw
Published at: 02.12.2016
Article status: Open
Licence: None
Percentage share of authors:
Article corrections:
-Publication languages:
EnglishView count: 2074
Number of downloads: 872